Clin2
NCT07668557Possibly a fitRecruiting

CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia

Acute Myeloid Leukemia (AML)

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must be between 18 and 70 years old.
  • You must have acute myeloid leukemia that has returned or is not improving after standard treatment.
  • Your leukemia cells must test positive for both CLL-1 and CD33 markers (a lab test will check this).
  • You must be well enough to carry out daily activities (ECOG score 0-2).
  • You must not have had CAR-T cell therapy or any other gene-modified cell therapy before.
  • You must not have serious organ problems (kidney, liver, heart) or active uncontrolled infections.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07841002Not yet recruiting· Phase 1
CLL-1 CAR-T cell therapy for relapsed or refractory leukemia

This trial tests an experimental CAR-T cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. It uses a special marker on leukemia cells (CLL-1) to target and kill them.

Beijing
NCT06760260Recruiting· Early Phase 1
FLT3-targeted CAR-T cell therapy for relapsed AML

This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.

Suzhou, Jiangsu
NCT07432100Not yet recruiting· Phase 1
CLL1 car-t cells for relapsed or refractory acute myeloid leukemia

This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.

NCT07538713Not yet recruiting· Phase 1
CAR-T therapy for hard-to-treat acute myeloid leukemia

This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.

NCT06762132Recruiting· Early Phase 1
CD33 car-t cell therapy for returning or hard-to-treat aml

This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.

Hangzhou, Zhejiang
NCT06326021Recruiting· Phase 1
CD33 CAR T for relapsed or refractory AML

This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.

Shanghai, Shanghai Municipality

Hear when a new Acute Myeloid Leukemia (AML) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.